HCW Biologics holds a minority equity interest in Wugen
MIRAMAR, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, congratulates Wugen, Inc. ("Wugen") on its recently announced $115 million equity financing led by Fidelity Management & Research Company, with participation from RiverVest Venture Partners, Lightchain Capital, Abingworth, ICG, LYZZ Capital, Tybourne Capital Management, Aisling Capital Management, and other leading life sciences investors.
HCW Biologics holds a minority equity interest in Wugen which it received as a license fee for the 2020 Wugen Exclusive License Agreement. Since inception, the Company recognized $16.2 million of revenues under the license agreement derived from an upfront license fee, paid in cash and shares of Wugen common stock, and product sales for clinical material ordered by Wugen for its clinical trials.
Dr. Hing C. Wong, the Company's Founder and CEO, stated, "As a shareholder of Wugen, we are excited to see a high-quality syndicate of institutional investors support Wugen's continued development of their next generation of allogeneic, off-the-shelf CAR-T cell therapies."
About HCW Biologics:
HCW Biologics Inc. (NASDAQ:HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies ...
